Latest Deals

Credit: Michael Vi / Shutterstock.

Integra LifeSciences has entered a definitive agreement to acquire Acclarent from J&J’s MedTech company, Ethicon. Integra will pay $275m in cash at closing, subject to customary purchase price adjustments. J&J will also be entitled to receive an additional $5m in regulatory milestone-based payments. The deal is expected to close by Q2 FY 2024. This acquisition presents Integra with a rare opportunity to become a key player in the ENT segment. 

Carl Zeiss Meditec has entered an agreement to acquire Dutch Ophthalmic Research Center to expand its ophthalmic device portfolio. As per the agreement, Zeiss will acquire 100% of the shares in DORC from the French investment firm, Eurazeo. Zeiss plans to expand its portfolio of vitreoretinal surgical devices through the acquisition.

Medical artificial intelligence (AI) company Lunit has signed an agreement to acquire Volpara Health Technologies in a deal valued at around A$292m ($193m). As part of the scheme implementation agreement, Lunit will acquire all shares of Volpara at a rate of A$1.15 ($0.75) per share through a New Zealand scheme of arrangement.

GRIP Molecular Technologies and Molecular Testing Labs (MTL) have announced a collaboration, which involved a successful clinical feasibility study of an advanced electronic biosensor technology. The aim is to deliver lab-quality, multi-disease diagnostic test results directly to consumers within minutes. The disposable diagnostic cartridge of GRIP utilises samples collected by the user and deploys a standard smartphone to show test results.